Última actualización 12 de septiembre de 2026
Key finding
The achievement rate of HbA1c (< 6.5%) was higher in the GA-guided therapy group than in the standard therapy group (40.5% vs. 25.3%, p = 0.034).
This study evaluated the effectiveness of glycated albumin (GA)-guided therapy versus standard therapy in patients with type 2 diabetes. GA-guided therapy showed a higher achievement rate of HbA1c < 6.5%.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the effectiveness of glycated albumin (GA)-guided therapy versus standard therapy in patients with type 2 diabetes. GA-guided therapy showed a higher achievement rate of HbA1c < 6.5%.
These findings suggest that GA-guided therapy could be a more effective approach for certain patients with type 2 diabetes, particularly those aiming for stricter glycemic control. Improved management of blood sugar levels can lead to better long-term health outcomes and reduce the risk of diabetes-related complications.
The study's sample size may limit the generalizability of the findings. The follow-up period was only 12 weeks, which may not capture long-term effects. The study did not include diverse populations, potentially affecting applicability.
Published in
Publication details and source links for this paper.
Qian R, Rui Z, Wei H, et al. Glycated Albumin-Guided Therapy in Patients with Type 2 Diabetes: A Multicenter, Randomized Controlled Trial. Journal of Diabetes. 2026;18(8):e70263. doi:10.1111/1753-0407.70263
GA-guided therapy group achieved HbA1c < 6.5% at a rate of 40.5% compared to 25.3% in the standard therapy group (p = 0.034).
No significant difference in achievement rate of HbA1c < 7% between groups (64.3% vs. 64.4%, p = 0.99).
Improvements in HbA1c, HOMA-β, insulin resistance, body weight, and waist circumference were better in the GA-guided therapy group.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Standard treatment, Ultrasound-guided pulsed radiofrequency therapy of the stellate ganglion and Achievement of HbA1c ≤ 6.5%, Body weight, HbA1c, and 3 more.
This study contributes evidence to
Primary intervention
Standard treatment
Primary outcomes
Evidence topics
Primary intervention
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
4
Related topics
12
Evidence pairs
1150
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Tema de evidencia
matched_outcome
Evidencia relacionada
Tema de evidencia
Guardar evidencia
Core evidence
The primary outcomes reported in this study.
Standard treatment → Achievement of HbA1c ≤ 6.5%
Standard treatment → Achievement of HbA1c ≤ 6.5%
Standard treatment → Homeostatic Model Assessment of Beta-cell function (HOMA-β)
Standard treatment → Homeostatic Model Assessment of Beta-cell function (HOMA-β)
Ultrasound-guided pulsed radiofrequency therapy of the stellate ganglion → Achievement of HbA1c ≤ 6.5%
Ultrasound-guided pulsed radiofrequency therapy of the stellate ganglion → Achievement of HbA1c ≤ 6.5%
Ultrasound-guided pulsed radiofrequency therapy of the stellate ganglion → Body weight
Ultrasound-guided pulsed radiofrequency therapy of the stellate ganglion → Body weight
Ultrasound-guided pulsed radiofrequency therapy of the stellate ganglion → HbA1c
Ultrasound-guided pulsed radiofrequency therapy of the stellate ganglion → HbA1c
Ultrasound-guided pulsed radiofrequency therapy of the stellate ganglion → Homeostatic Model Assessment of Beta-cell function (HOMA-β)
Ultrasound-guided pulsed radiofrequency therapy of the stellate ganglion → Homeostatic Model Assessment of Beta-cell function (HOMA-β)
Ultrasound-guided pulsed radiofrequency therapy of the stellate ganglion → Insulin resistance
Ultrasound-guided pulsed radiofrequency therapy of the stellate ganglion → Insulin resistance
Ultrasound-guided pulsed radiofrequency therapy of the stellate ganglion → Waist circumference
Ultrasound-guided pulsed radiofrequency therapy of the stellate ganglion → Waist circumference
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Standard treatment and Body Weight, Standard treatment and HbA1c.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring Body Weight
Measures Body Weight as a key outcome.
All studies measuring HbA1c
Measures HbA1c as a key outcome.
All studies on Standard treatment
Contributes to Standard treatment evidence base.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
3 results
3 results
3 results
3 results
3 results
Generated from the study's connected evidence using Evidence Intelligence™.
Standard treatment may affect body weight.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
Body weight
EvidenceScore™ Strong | EvidenceScore™ 79.0 | weak positive | ConsistencyScore™ Generally Consistent | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Standard treatment may lower HbA1c.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 79.0 | weak positive | ConsistencyScore™ Generally Consistent | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Standard treatment may improve insulin resistance.
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Ranked evidence signals
Insulin resistance
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
Standard treatment appears to improve homeostatic model assessment of beta-cell function (homa-β).
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Homeostatic Model Assessment of Beta-cell function (HOMA-β)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Centrada en la evidencia, no en la publicidad.
Tus datos siempre están protegidos.
Se agregan nuevos estudios todos los días.
